SAN FRANCISCO, CA, Aug 06, 2015 (Marketwired via COMTEX) -- Medivation, Inc. MDVN, +0.89% today reported its financial results for the second quarter ended June 30, 2015. U.S. net sales of XTANDI(R) (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $298.4 million for the quarter (+108% vs. prior year). Second quarter U.S. net sales increased by 33% compared with first quarter 2015 net sales of $224.0 million. We estimate second quarter 2015 unit demand increased by a low- to mid-teens percentage rate, compared with unit demand in the first quarter 2015. In addition, based on information provided by Astellas, a lower gross-to-net discount rate was applied to second quarter gross sales (compared with the first quarter rate), and a $2.8 million favorable adjustment was recorded in the second quarter by Astellas with respect to gross-to-net discount related to previous period gross sales.
Help employers find you! Check out all the jobs and post your resume.
